Tissium is a biotechnology company focused on the development of biomorphic programmable polymers for tissue reconstruction. Their approach aims to provide solutions that mimic the native environment of tissues, potentially revolutionizing the field of regenerative medicine.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.

Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.

Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.

We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

BNP Paribas

Bpifrance

CM-CIC Capital Prive

Sofinnova Partners

European Investment Fund

Omnes Capital

Karista

Cathay Capital

Cathay Health

Crédit Mutuel Innovation

Mérieux Equity Partners

Merieux Developpement

Fonds Stratégique d'Investissement

IBD Ventures

TISSIUM

Tissium

COM:TISSIUM

Tissium

Analysis Not Available